VT-Covid-19: Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology

Sponsor

University Hospital, Strasbourg, France (Other)

Overall Status

Completed

CT.gov ID

NCT04452422

Collaborator

(none)

Enrollment

Location

Actual Duration (Months)

9.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Severe SARS-CoV-2 infection, responsible of COVID-19, is accompanied by many venous thromboembolic events. Antithrombotic treatment is the cornerstone of management of many neurovascular diseases (NVDs) and the benefit-risk ratio is crucial to avoid hemorrhagic complications. Therefore, in non-severe COVID-19 patients affected by NVDs, the diagnostic of deep venous thrombosis (DVT) is challenging. Using bedside Doppler ultrasonography (DUS) of lower limbs, this study investigated the rates of DVT in these patients in stroke unit.

Condition or Disease	Intervention/Treatment	Phase
Deep Venous Thrombosis

Study Design

Study Type:

Observational

Actual Enrollment :

30 participants

Observational Model:

Case-Only

Time Perspective:

Other

Official Title:

High Prevalence of Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology

Actual Study Start Date :

Jun 23, 2020

Actual Primary Completion Date :

Sep 23, 2020

Actual Study Completion Date :

Sep 23, 2020

Outcome Measures

Primary Outcome Measures

Number of cumulated deep venous thrombosis among the hospitalization [Day 7 after admisssion]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Inclusion criteria:
Age>18 years
COVID-19 confirmed with RT-PCER and/or chest CT-scan
Acute neurovascular disease defined as transient ischemic attack or acute ischemic stroke or venous cerebral thrombosis or hemorrhagic stroke.
Exclusion criteria:
age<18
Other neurovascular diseases